A year ago, on 03 Aug 2012, ACAD closed at $1.5. Now, it is trading around $22. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc.
With at least a dozen upcoming Orphan Indications, LymPro, NuroPro, MANF patents in Europe and the US, I see AMBS entering multiple collaborations with the leading pharmaceutical companies in the world over the next 12 months. LymPro validation (to be announced next week) and CLIA collaboration will take AMBS to $0.5-1.00. I expect AMBS to be trading atleast at $10 (150X current pps) by Dec 2014.
In a recently completed pre-clinical model of Parkinson's disease funded by MJFF, MANF corrected the neurological deficits when it was given immediately after the animals became sick. MANF also corrected the neurological deficits when it was given three weeks after the models became sick. This means that MANF is able to prevent the death of healthy dopaminergic neurons, but also MANF can save dopaminergic neurons that are already dying.
How do these results apply to human patients? The results suggest that in patients newly diagnosed with Parkinson's disease MANF might be able to save those dopaminergic neurons that are sick and dying, but not yet dead. These patients will likely get better sooner, and their recovery will also last for a longer time. It is much too soon to predict whether MANF will be able to cure Parkinson's disease. MANF is certainly one of the most promising molecules currently in development to treat this debilitating disease.
